

14<sup>th</sup> August 2023

Ref : KIMIABL/COMP/BSE/23-24/24

To  
**Department of Corporate Affairs- Listing**  
**BSE Limited**  
Phiroz Jeejeebhoy Towers,  
Dalal Street, Fort Mumbai-400001

**Scrip Code: 530313 [KIMIABL]**

**Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.**

Dear Sir/Madam,

The meeting of Board of Directors of the Company was held today on Monday, August 14, 2023 at 4.00 pm (IST) at the corporate office of the Company, situated at 974, 9<sup>th</sup> Floor, Aggarwal Millennium Tower-II, Netaji Subash Place, New Delhi-110034 and the following businesses, amongst others, were transacted at the meeting of the Board of Directors.

1. Approval of un-audited financial results of the Company, on standalone basis, as at/for the quarter and three months ended June 30<sup>th</sup> 2023, in accordance with Regulation 33 of SEBI (Listing Obligation and Disclosure) Requirements) Regulations, 2015 and taking on record the Limited Review Report issued by the Statutory Auditor of the Company ( copy attached as **Annexure A**).
2. Re-appointment of M/s Rahul Chaudhary & Associates as Secretarial Auditor of the Company for the financial year 2022-23 was taken on record.
3. Re-appointment of M/s. JKVS & Co., Chartered Accountants, (FRN No. 318086E), as Internal Auditors of the Company for the financial year 2023-24 in accordance with Section 138 of the Companies Act, 2013 was taken on record.
4. Re-appointment of M/s. Mahesh Singh & Co, Cost Accountants (FRN: 100441), as the Cost Auditors of the Company for the Financial Year 2023-24 under Section 148 of the Companies Act, 2013 was taken on record.

You are requested to take the above information on record and disseminate the same on your website.

The meeting was concluded at 05:45 pm.

Thanking You,  
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**

  
**Lakshay Prakash**  
CFO & Company Secretary



**KIMIA BIOSCIENCES LIMITED**

**Regd. Office/Works**  
Village Bhondsi, Damdama Lake Road,  
Gurugram, Haryana -122102  
Tel.: +91 9654746544, 9654206544

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

**Corporate Office**

974, 9<sup>th</sup> Floor, Aggarwal Millenium Tower-II  
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA  
Tel.: +91 11 47063600, 470630601

**KIMIA BIOSCIENCES LIMITED**

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023**

(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Year Ended
		30-06-2023	31-03-2023	30-06-2022	31-03-2023
		(Unaudited)	(Audited) Refer Note 2	(Unaudited)	(Audited)
I	Revenue from Operations	2,423.01	2,266.30	3,658.48	12,851.60
II	Other Income	12.52	36.31	45.25	121.31
III	<b>Total Income (I+II)</b>	<b>2,435.53</b>	<b>2,302.61</b>	<b>3,703.73</b>	<b>12,972.91</b>
IV	<b>Expenses:</b>				
	a) Cost of materials consumed	1,890.92	1,717.11	2,865.58	10,639.34
	b) Change in inventories of finished goods and work-in-progress	(101.67)	71.52	(292.30)	(1,036.22)
	c) Employee benefits expenses	398.70	488.49	386.27	1,640.30
	d) Finance costs	127.58	126.09	83.07	424.50
	e) Depreciation and amortisation expense	83.21	86.83	79.72	333.23
	f) Other expenses	398.95	525.58	432.45	2,105.77
V	<b>Total Expenses (IV)</b>	<b>2,797.69</b>	<b>3,015.62</b>	<b>3,554.79</b>	<b>14,106.92</b>
VI	<b>Profit/(loss) before exceptional items and Tax (III-V)</b>	<b>(362.16)</b>	<b>(713.01)</b>	<b>148.94</b>	<b>(1,134.01)</b>
VII	Exceptional Items	-	104.80	-	104.80
VIII	<b>Profit/(loss) before tax (VI-VII)</b>	<b>(362.16)</b>	<b>(817.81)</b>	<b>148.94</b>	<b>(1,238.81)</b>
IX	<b>Tax expenses:</b>				
	a) Current Tax	-	-	-	-
	b) Deferred Tax charge / (credit)	(91.11)	(201.31)	38.72	(303.59)
X	<b>Profit/(loss) for the period (VII-IX)</b>	<b>(271.05)</b>	<b>(616.50)</b>	<b>110.22</b>	<b>(935.21)</b>
XI	<b>Other Comprehensive Income</b>				
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)				
	- Remeasurement of defined benefit plans	-	(7.33)	-	(7.33)
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-
XII	<b>Total Comprehensive Income for the period (X+XI)</b>	<b>(271.05)</b>	<b>(623.83)</b>	<b>110.22</b>	<b>(942.55)</b>
XIII	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13
XIV	<b>Other Equity</b>				73.15
XV	<b>Earnings per equity share (not annualised)</b>				
	Basic in Rs.	(0.57)	(1.30)	0.23	(1.98)
	Diluted in Rs.	(0.57)	(1.30)	0.23	(1.98)

**Other Notes**

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for three months ended March 31, 2023 are the balancing figure between audited figures in respect of the full financial year and published year to date figures up to the nine months of the previous financial year.
- During the financial year 22-23, a penalty of ₹104.80 Lakhs was imposed by the Haryana State Pollution Control Board for non-compliance with certain regulations. The same has been provided in previous quarter and disclosed as exceptional item.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2023.



FOR KIMIA BIOSCIENCES LIMITED

Vipul Goel  
(Director)  
DIN - 00064274

Date : August 14, 2023

Place : New Delhi



**Independent Auditor's Review Report on Unaudited Financial Results for the quarter ended June 30, 2023 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended**

**To the Board of Directors of Kimia Biosciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Kimia Biosciences Limited ("the Company") for the quarter ended June 30, 2023. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co.  
Chartered Accountants  
Firm Registration No. 302049E



Place: Noida (Delhi- NCR)  
Date: August 14, 2023

Bimal Kumar Sipani  
Partner  
Membership No. 088926  
UDIN: 23088926BGXBGI9846